Abacavir - instructions for use of the drug, structure, Contraindications

When ATH:
J05AF06

Characteristic.

Nucleoside analogues.

Pharmacological action.
Antiviral, inhibiting HIV reverse transcriptase.

Application.

HIV infection (combination therapy).

Contraindications.

Hypersensitivity.

Restrictions apply.

Liver disease, Early infancy (to 3 Months), breast-feeding.

Pregnancy and breast-feeding.

Category actions result in FDA - C. (The study of reproduction in animals has revealed adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not held, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk.)

Side effects.

Delayed-type hypersensitivity (sometimes life-threatening): fever, malaise, fatiguability, gastrointestinal disorders (dry mouth, nausea, vomiting, diarrhea, abdominal pain), cough, breathlessness, low blood pressure, swelling and pain in the joints, headache, weakness, sleep disorders, decreased appetite, gepatomegaliya, hepatic steatosis, pancreatitis, lactic acidosis, rash.

Cooperation.

Possible competition for alcohol dehydrogenase with drugs, metabolized during its participation (retinoids).

Dosing and Administration.

Inside, regardless of the meal, in strictly defined hours, adults and adolescents over 12 years - 1 Table. (300 mg) or 15 ml (an inability or the inability to swallow tablets) 2 once a day, Children from 3 Months before 12 years - 8 mg / kg body weight 2 once a day, but not more 600 mg.

Precautions.

Monotherapy is not allowed. Prescribers can only specialist, with experience in the treatment of HIV infection. Before the start of the active anti-retroviral therapy is conducted full clinical and laboratory examination of the patient, incl. level is determined on the plasma viral load and number of CD4 T-lymphocyte. During treatment a regular shows (every 3-6 months) assessment of the level of the replication process, plasma viral load (bDNA determination and RT-PCR) and the level of CD4 cells. In the presence of clinical symptoms of HIV therapy should begin to exclude CD4 cell number and viral load on the plasma. The appearance of any signs of hypersensitivity reactions (commonly found in the first 6 weeks of treatment) because of their potential danger to life requires discontinuation (and further use of the drug is unacceptable). Patients should be warned, that the treatment does not reduce the risk of transmission of HIV to others.

Cooperation